Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Clin Exp Dermatol
; 47(10): 1857-1858, 2022 Oct.
Article
em En
| MEDLINE
| ID: mdl-35633107
ABSTRACT
Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer. BRAF inhibitors have been reported to be associated with new and changing melanocytic lesions, including eruptive naevi. We describe two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF-mutant metastatic colorectal cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Retais
/
Neoplasias Cutâneas
/
Neoplasias do Colo
/
Exantema
/
Nevo Pigmentado
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Exp Dermatol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Reino Unido